Ultra-T Therapeutics

Ultra-T Therapeutics is an emerging biotechnology company focused on the development of next-generation CAR-T cell therapies. Founded by Dr. Michel Sadelain, a pioneer in synthetic immunology and CAR-T technology, the company leverages its 'Ultra-T' platform to engineer T cells with optimized signaling domains and enhanced metabolic fitness. This technology aims to address the critical limitations of current cell therapies, specifically seeking to improve efficacy in solid tumors and achieve durable remissions in autoimmune diseases such as lupus. Backed by top-tier venture capital firms, the company is translating decades of research from Memorial Sloan Kettering Cancer Center into a commercial pipeline of highly sensitive and persistent immune cell products.